Long-term survival after multimodality treatment for resectable pancreatic cancer.
BACKGROUND
The prognosis of pancreatic adenocarcinoma after radical pancreatectomy is poor, especially in advanced-stage disease.


OBJECTIVE
To determine the survival rates and evaluate the effectiveness of multimodality treatment for advanced pancreatic cancer.


METHODS
From November 1983 to January 1993, 30 patients with pancreatic adenocarcinoma including 9 with carcinoma of the body and tail were treated by a multimodal approach consisting of extended pancreatectomy, intraoperative radiotherapy (IORT), and hepatic artery or portal vein infusion of mitomycin C (MMC) followed by systemic bolus injection. All surviving patients were followed for more than 8 yr and survival rates were calculated by the Kaplan-Meier method.


RESULTS
There were no operative or hospital deaths. Eight patients survived for more than 5 yr, 3 of whom survived more than 10 yr. The 5-yr survival rate for 27 patients excluding 3 with metastasis to the liver, peritoneum, or lung was 31%, with a median survival of 31.1 mo. Among them, the 1-, 3-, and 5-yr survival rates for 19 patients with regional nodal metastasis were 95, 50, and 28%, respectively, with a median survival of 36.0 mo.


CONCLUSIONS
The multimodality treatment combined with IORT and MMC chemotherapy appeared to have a benefit for prognosis of advanced pancreatic adenocarcinoma.
Ozaki
H
H
Department of Surgery, National Cancer Center Hospital, Tokyo, Japan. ozakihdo@aol.com
Kinoshita
T
T
Kosuge
T
T
Shimada
K
K
Yamamoto
J
J
Tokuuye
K
K
Fukushima
N
N
Mukai
K
K
D000230:Adenocarcinoma / Q000401:mortality / Q000628:therapy*; D000368:Aged; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D016685:Mitomycin / Q000008:administration & dosage; D010180:Pancreatectomy; D010190:Pancreatic Neoplasms / Q000401:mortality / Q000628:therapy*; D015996:Survival Rate; D017741:Survivors
D016685:Mitomycin